Trends in Parasitology
OpinionMalaria Parasite Clearance: What Are We Really Measuring?
Section snippets
Assessing Drug Efficacy in Malaria
Malaria was responsible for approximately 435 000 deaths in 2017 [1]. Mortality from malaria fell by 28% between 2010 and 2017 [1], in part because of the increased use of highly effective artemisinin-based therapies as the first-line treatment for malaria [2., 3., 4.]. However, artemisinin-resistant Plasmodium falciparum has been confirmed in a number of locations across South-East Asia, raising global concerns that malaria mortality will increase unless we can replace the current failing
Interpreting the Parasite Clearance Curve
The rate at which parasites disappear from a host’s circulation has been measured in a variety of ways (Box 1), and it is usually interpreted as a measure of the speed of drug activity. However, the rate of parasite clearance may not only depend on how quickly a drug acts, but also on how quickly drug-affected parasites are removed from circulation by the host [21., 22., 23., 24.]. To illustrate, let us imagine two extreme scenarios of drug action and parasite removal that have very different
Evidence for Drug Killing and Delayed Clearance
If the killing and delayed clearance scenario is correct, it implies that drugs act faster than we currently estimate by measuring the decline in parasitaemia alone, and that a population of killed parasites circulate for a period before removal. In this case, we would mistakenly classify some circulating parasites as ‘healthy’ in our measurements of parasite concentration (by microscopy or PCR), while in fact they are severely drug affected. We have recently investigated the viability of
Reinterpreting the Parasite Clearance Curve
It is clear from the evidence outlined that ‘parasite clearance’ is a composite measure, encapsulating both drug killing and rate of removal of drug-affected parasites from circulation. Thus, in a scenario where parasite numbers drop rapidly after treatment, there are a variety of possible scenarios that may cause this decline (Figure 1D,E). Figure 1E illustrates this, with contour lines showing the observed parasite clearance half-life for different combinations of the rates of drug killing
Implication 1: Delayed Clearance Confounds Forecasts of Drug Killing and Ideal Dosing Regimens
PK/PD models play a central role in drug development and dose-optimisation studies. In particular, PK/PD models are important for projecting the total fold reduction in parasite numbers following treatment with a candidate antimalarial drug [12,13]. It is important to understand the limitations of these models, because forecasts based on these will only ever be as accurate as the assumptions used to generate them. For example, a usual concern with forecasting drug killing forward is that it
Implication 2: Parasite Clearance Curve May Not Be the Optimal Method for Comparing Drug Killing Activity
Drug-affected parasites are not always immediately removed from circulation after they are killed by treatment. Therefore, our ability to compare drug killing between different drugs may be limited. If all drugs induced the same rate of removal of drug-affected parasites, then comparing drugs based on the rate of decline of total circulating parasite numbers may not be sensitive to differences in parasite killing rate [23]. For example, if two treatments induced killing at different rates, one
Translation to Clinical Efficacy: Lessons from the Artemisinins
Thus far we have highlighted that the key in vivo metric to assess the parasiticidal efficacy of a new candidate antimalarial drug – the parasite clearance half-life – is not measuring drug killing alone, and so may not be an ideal metric of parasiticidal efficacy. However, at this point it is worth considering whether parasiticidal efficacy and clinical efficacy may be best assessed in different ways. For example, if the presence of parasites (even dead ones) contributes to pathogenesis, then
Proposal to Measure Parasite Viability in Future Studies: Prospects and Challenges
To improve our understanding of drug efficacy and parasite viability after drug treatment in malaria we must improve and develop new methods for assessing parasite viability. By directly quantifying the viability of circulating parasites after drug treatment one will be able to understand whether the decline in circulating parasite concentration reflects drug killing activity, or whether it reflects host removal of drug-affected parasite. The question arises of how to assess viability?
Viability
Concluding Remarks
Artemisinin resistance is a growing threat to global efforts to eliminate malaria. This has driven a large global investment in the development of new antimalarial drugs and now is a critical moment in drug development efforts. How we assess and prioritise new compounds for development is a decision that may define the success of current drug-development campaigns. We advise caution in interpreting the parasite clearance curve as a measure of a drug’s killing rate. The use of the parasite
Acknowledgements
The complete list of authors includes those named in the author list, as well as the members of the Interdisciplinary Approaches to Malaria Consortium which includes Deborah Cromer, Maria Rebelo, Pengxing Cao, James M. McCaw, Julie A. Simpson, Jennifer A. Flegg, Danny W. Wilson, Nicholas M. Anstey, and James S. McCarthy. All authors contributed directly to the development of the ideas and writing of this publication. Spacing requirements precluded naming all authors explicitly in the author
Glossary
- Clinical efficacy
- a drug’s ability to improve clinical outcomes in patients. Examples of measures of clinical efficacy include the speed with which a drug resolves the patient’s symptoms (e.g., fever clearance time) and improvement in survival outcomes.
- Delayed death
- usually refers to the action of apicoplast inhibitors, such as doxycycline, which do not kill the current parasite stages, but damage daughter parasites, which are not able to establish infection in a new red blood cell once released.
References (70)
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
Lancet
(2010)Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
Lancet
(2012)Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study
Lancet Infect. Dis.
(2016)Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
Lancet Infect. Dis.
(2017)Artesunate–mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial
Lancet Infect. Dis.
(2016)Mathematical modelling to guide drug development for malaria elimination
Trends Parasitol.
(2017)Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice
Int. J. Parasitol.
(2018)Characterizing the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo
Int. J. Parasitol.
(2017)Antimalarial activity of mefloquine and qinghaosu
Lancet
(1982)- et al.
Treatment of malaria – some considerations and limitations of the current methods of assessment
Trans. R. Soc. Trop. Med. Hyg.
(1989)
A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection
J. Theor. Biol.
Prognostic significance of rises in parasitemia during treatment of falciparum-malaria
Trans. R. Soc. Trop. Med. Hyg.
Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy
Trends Parasitol.
World malaria Report 2018
World Malaria Report 2016
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
Lancet
Artemisinin resistance in Plasmodium falciparum malaria
N. Engl. J. Med.
Spread of artemisinin resistance in Plasmodium falciparum malaria
N. Engl. J. Med.
The parasite clearance curve
Malar. J.
Malaria parasite clearance
Malar. J.
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs
PLoS One
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Nat. Rev. Drug Discov.
New developments in anti-malarial target candidate and product profiles
Malar. J.
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR
Antimicrob. Agents Chemother.
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study
Malar. J.
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
Proc. Natl. Acad. Sci. U. S. A.
Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial
Clin. Infect. Dis.
How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance?
Antimicrob. Agents Chemother.
Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort
Proc. Natl. Acad. Sci. U. S. A.
Within-host modeling of blood-stage malaria
Immunol. Rev.
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria
J. Infect. Dis.
Intrahost modeling of artemisinin resistance in Plasmodium falciparum
Proc. Natl. Acad. Sci. U. S. A.
Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance
PLoS Biol.
Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine
Am. J. Trop. Med. Hyg.
Viability of Plasmodium falciparum ex vivo: comparison of the effects of artemether and sulfadoxine-pyrimethamine
Eur. J. Clin. Pharmacol.
Cited by (19)
Quantification of Plasmodium falciparum HRP-2 as an alternative method to [<sup>3</sup>H]hypoxanthine incorporation to measure the parasite reduction ratio in vitro
2023, International Journal of Antimicrobial AgentsEffect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
2022, The Lancet Infectious DiseasesNew insights into the spread of resistance to artemisinin and its analogues
2021, Journal of Global Antimicrobial ResistanceCitation Excerpt :This medicinal compound also acts as an anticancer agent [34–39]. However, it is more difficult to define and explain artemisinin resistance, typically knowing the fact that, following antimalarial treatment with an artemisinin derivative, parasites are removed from the bloodstream very differently involving the spleen [40–43]. Artemisinin is suggested to be a prodrug, and activation of artemisinin involves cleavage of the endoperoxide moiety by iron of heme; this process occurs within the erythrocytes and produces reactive oxygen species that attack the nucleophilic groups of parasitic proteins and lipids.
‘Artemisinin Resistance’: Something New or Old? Something of a Misnomer?
2020, Trends in ParasitologyCitation Excerpt :Careful evaluations of AS monotherapy trials have shown no associations of PCTs (or ring-stage clearance half-life) with recrudescences [24,55], and longer PCTs did not correspond to delayed resolutions of malaria fever [23,55]. Evidence that the clearance curve does not measure the rate of killing by the drug [56] is in accord with those evaluations. Likewise, various genetic markers and measures of parasite ART response in vitro ring-stage survival assays (RSAs, IC50s) have not associated with the recrudescences of monotherapy failure (Box 3).
- 5
The complete author list is provided in the acknowledgements